BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

Post-LOE

butalbital, acetaminophen, caffeine, and codeine phosphate

Teva

ANDAORALCAPSULE

Approved

Jun 2004

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE (butalbital, acetaminophen, caffeine, and codeine phosphate) by Teva is butalbital, a barbiturate, is a gaba a receptor agonist and may inhibit excitatory ampa receptors. Approved for the symptom complex of tension (or muscle contraction) headache, other non-opioid analgesic, alternative treatments are inadequate. First approved in 2004.

Drug data last refreshed 18h ago

Mechanism of Action

Butalbital, a barbiturate, is a GABA A receptor agonist and may inhibit excitatory AMPA receptors. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions. Caffeine is a methylxanthine and CNS stimulant. The exact mechanism…

Pharmacologic Class:

Barbiturate

Indications (3)

the symptom complex of tension (or muscle contraction) headache

Worked on BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.